Skip to main content

Advertisement

SpringerLink
Log in

Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible and accurate in women with advanced breast cancer?

  • Clinical Trials Report
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wilke LG, McCall LM, Posther KE, et al.: Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006, 13:491–500.

    Article  PubMed  Google Scholar 

  2. Krag DN, Anderson SJ, Julian TB, et al.: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node resection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8:881–888.

    Article  PubMed  CAS  Google Scholar 

  3. Mansel RE, Fallowfield L, Kissim M, et al.: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006, 98:599–609.

    Article  PubMed  Google Scholar 

  4. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165–4174.

    Article  PubMed  CAS  Google Scholar 

  5. Xing Y, Foy M, Cox DD, et al.: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006, 93:539–546.

    Article  PubMed  CAS  Google Scholar 

  6. Shen J, Gilcrease MZ, Babiera GV, et al.: Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 2007, 109:1255–1263.

    Article  PubMed  Google Scholar 

  7. Gianni L, Semiglazov V, Manikhas GM, et al.: Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumor safety analysis. J Clin Oncol 2007, 25(Suppl):532.

    Google Scholar 

  8. Buzdar AU, Valero V, Ibrahim NK, et al.: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patient treated with the same regimen. Clin Cancer Res 2007, 13:228–233.

    Article  PubMed  CAS  Google Scholar 

  9. Hennessy BT, Hortobagyi GN, Rouzier R, et al.: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005, 23:9304–9311.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Kelly K. Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hunt, K.K. Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible and accurate in women with advanced breast cancer?. Curr Breast Cancer Rep 1, 65–67 (2009). https://doi.org/10.1007/s12609-009-0009-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-009-0009-1

Keywords

Search

Navigation